

Table 3 Treatments and outcomes of patients with coronavirus disease 2019 (COVID-19) in high altitude areas

	Disease severity				
Treatments and outcomes	All patients (n=67)	Severe patients (n=4)	Non-severe patients (n=39)	Asymptomatic patients (n=24)	p value
Treatments- No./total No. (%)					
Antiviral therapy	25/56(44.6)	2/4(50.0)	16/33(48.5)	7/19(36.8)	0.765
Antibiotic therapy	9/56(16.1)	2/4(50.0)	6/33(18.2)	1/19(5.3)	0.062
Oxygen therapy	45/56(80.4)	4/4(100.0)	26/33(78.8)	15/19(78.9)	0.885
Supportive treatment	25/56(44.6)	2/4(50.0)	14/33(42.4)	9/19(47.4)	0.916
Outcomes-No. (%) :					
Staying in hospital	15(22.4)	1(25.0)	9(23.1)	5(20.8)	<0.001
Discharge from hospital	49(73.1)	0	30(76.9)	19(79.2)	
Transfer to another hospital	3(4.5)	3(75.0)	0	0	
Consecutively 2 nuclei acid tests negative for respiratory tract pathogen rate--No. (%) :	49(73.1)	0	30(76.9)	19(79.2)	0.043
Days from initial positive to subsequent negative nuclei acid tests -median (IQR), days	9.0(3.0-11.0)	-	9.0(4.8-11.3)	6.0(3.0-10.0)	0.216

For treatment, P values denoted the comparison between severe cases, non-severe cases and asymptomatic cases. For nuclei acid tests, P values denoted the comparison between non-severe cases and asymptomatic cases.

cases.